Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial-Reference-Cited by-同舟云学术

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

Published:2007-10-05 Issue:4 Volume:246 Page:483-489
ISSN:0721-832X
Container-title:Graefe's Archive for Clinical and Experimental Ophthalmology
language:en
Short-container-title:Graefes Arch Clin Exp Ophthalmol

Author:

Ahmadieh Hamid,Ramezani Alireza,Shoeibi Nasser,Bijanzadeh Bijan,Tabatabaei Ali,Azarmina Mohsen,Soheilian Masoud,Keshavarzi Gholamreza,Mohebbi Mohammad-Reza

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Link

http://link.springer.com/content/pdf/10.1007/s00417-007-0688-0.pdf

Reference25 articles.

1. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487

2. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME; Pan-American Collaborative Retina Study Group (2007) Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743–750

3. Audren F, Erginay A, Haouchine B, Benosman R, Conrath J, Bergmann JF, Gaudric A, Massin P (2006) Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: 6 month results of a prospective controlled trial. Acta Ophthalmol Scand 84:624–630

4. Audren F, Lecleire-Collet A, Erginay A, Haouchine B, Benosman R, Bergmann JF, Gaudric A, Massin P (2006) Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 142:794–799

5. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855–849

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing the efficacy of glucocorticoids and anti-VEGF in treating diabetic macular edema: systematic review and comprehensive analysis;Frontiers in Endocrinology;2024-03-22

2. A Review on Diabetic Retinopathy;Current Diabetes Reviews;2023-10-20

3. Anti-VEGF combined with ocular corticosteroids therapy versus anti-VEGF monotherapy for diabetic macular edema focusing on drugs injection times and confounding factors of pseudophakic eyes: A systematic review and meta-analysis;Pharmacological Research;2023-10

4. Outcome of Suprachoroidal Triamcinolone Acetonide in Resistant Diabetic Macular Edema;Pakistan Journal of Health Sciences;2023-07-31

5. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-06-27